Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25
PAT after MI is Rs. 41 crore which is 162% increase
PAT after MI is Rs. 41 crore which is 162% increase
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The brand Magtein by Threotech has a sales value of approximately US $438 million
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
Subscribe To Our Newsletter & Stay Updated